Find your next paid study

Massachusetts General HospitalNCT05570812

Confirmatory Efficacy Randomized Clinical Trial of Amygdala Neurofeedback for Major Depressive Disorder

The goal of this study is to evaluate whether rtfMRI-nf training to increase the amygdala response to positive memories may serve as a stand-alone intervention…

Kymberly YoungNCT05703256

~$10 – $7,500

Phase 4

A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms

This is a randomized, double-blind, active-controlled, multi-center study to evaluate the efficacy of AXS-05, compared to bupropion, in preventing the relapse …

Axsome Therapeutics, Inc.NCT06223880

~$10 – $8,750

Phase 1

A Phase I/II Study of PDC-1421 for Treating Depression in Cancer Patients: Part I Dose Escalation

The purpose of this study is to evaluate the safety and the effective doses of PDC-1421 in cancer patients with depression.

~$10 – $8,750

BioLite, Inc.NCT03833206

Posttraumatic Stress Disorder (PTSD)AnxietyDepression - Major Depressive Disorder

Mindful Self-Compassion to Address PTSD and Substance Use in Unhoused Women

Trauma exposure, posttraumatic stress disorder (PTSD), and substance use disorder (SUD) present major threats to public health. PTSD and SUD are major correlat…

University of California, Los AngelesNCT06646692

Major Depressive DisorderEpilepsy

Investigating the Neural Mechanisms of Repetitive Brain Stimulation With Invasive and Noninvasive Electrophysiology in Humans

Transcranial magnetic stimulation (TMS) is an effective treatment for depression, but clinical outcome is suboptimal, partially because investigators are missi…

Stanford UniversityNCT05996900

Phase 2

A Pilot, Phase II, Open-Label, Single-Center Study of Sodium-Glucose Cotransporter-2 Inhibitor Empagliflozin in Major Depressive Disorder

The primary purpose of this study is to determine whether empagliflozin, a medication in a class known as sodium-glucose cotransporter-2 inhibitors (SGLT2) inh…

NYU Langone HealthNCT05757791

~$10 – $7,500

Phase 3

Efficacy of Biomarker-guided rTMS for Treatment Resistant Depression

Repetitive transcranial magnetic stimulation (rTMS) is a treatment for depression. The investigators are continuing to learn how to optimize outcomes from rTMS…

Treatment Resistant DepressionMajor Depressive Disorder

Weill Medical College of Cornell UniversityNCT04041479

Phase 4

Central Cholinergic Dysfunction in Depression: PET Imaging of a Novel Treatment Target With [18F]VAT to Assess the Antidepressant Effect of Nicotine

In the brain, certain nerve cells communicate using a chemical called acetylcholine. Acetylcholine is thought to be important for several functions including m…

Major Depressive Disorder (MDD)

Stony Brook UniversityNCT07095205

Phase 2

Mindfulness Engaged Neurostimulation for Depression

Repetitive Transcranial Magnetic stimulation (rTMS) is an FDA-approved therapy for treatment resistant depression (TRD) that involves brief magnetic stimulatio…

DepressionTreatment Resistant DepressionMajor Depressive Disorder+2 more

University of California, San DiegoNCT07512284

Phase 2

The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects

The purpose of this study is to test the hypothesis that the anti-depressant and anti-suicidal effects of the N-methyl-D-aspartate receptor (NMDAR) antagonist …

Depressive DisorderMajor Depressive DisorderBipolar Disorder+2 more

Yale UniversityNCT05786066

Using Electrophysiology to Index Non-invasive Brain Stimulation Effects on Reward System Functioning in Depression

Depression is a leading cause of morbidity and mortality, conferring substantial healthcare and societal costs. By studying methods to non-invasively target ne…